Chemical Synthesis of (+)-Ryanodine and (+)-20-Deoxyspiganthine
Abstract
(+)-Ryanodine is a natural product modulator of ryanodine receptors, important intracellular calcium ion channels that play a critical role in signal transduction leading to muscle movement and synaptic transmission. Chemical derivatization of (+)-ryanodine has demonstrated that certain peripheral structural modifications can alter its pharmacology, and that the pyrrole-2-carboxylate ester is critical for high affinity binding to ryanodine receptors. However, the structural variation of available ryanodine analogues has been limited by the challenge of site-specific functionalization of semisynthetic intermediates, such as (+)-ryanodol. Here we report a synthetic strategy that provides access to (+)-ryanodine and the related natural product (+)-20-deoxyspiganthine in 18 and 19 steps, respectively. A key feature of this strategy is the reductive cyclization of an epoxide intermediate that possesses the critical pyrrole-2-carboxylate ester. This approach allows for the direct introduction of this ester in the final stage of the synthesis and provides a framework for the synthesis of previously inaccessible synthetic ryanoids.
Additional Information
© 2017 American Chemical Society. ACS AuthorChoice - This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Received: November 22, 2016; Published: March 9, 2017. The Caltech Center for Catalysis and Chemical Synthesis is gratefully acknowledged for access to analytical equipment. We thank Dr. Michael Takase and Larry Henling for acquiring the X-ray diffraction data and Julie Hofstra for solving the structures of compounds 1, 3, 16, and 18. Fellowship support was provided by the Shenzhen UV-ChemTech Inc. (postdoctoral fellowship to C.X.) and the NIH (training grant 5T32GM007616-37 to A.H.). S.E.R. is an American Cancer Society Research Scholar and Heritage Medical Research Institute investigator. Financial support from the NIH (NIGMS RGM097582-01, R35GM118191-01), Eli Lilly, and Novartis is gratefully acknowledged.Attached Files
Published - acscentsci.6b00361.pdf
Supplemental Material - oc6b00361_si_001.pdf
Supplemental Material - oc6b00361_si_002.cif
Supplemental Material - oc6b00361_si_003.cif
Supplemental Material - oc6b00361_si_004.cif
Supplemental Material - oc6b00361_si_005.cif
Files
Name | Size | Download all |
---|---|---|
md5:e66630a171098063d01246ad3116dece
|
3.3 MB | Preview Download |
md5:0f802ca911edb094e362ca7d7a1cf8fb
|
1.6 MB | Download |
md5:4342834c00e2359341bf02defd39f15c
|
2.8 MB | Download |
md5:48cc0200627ddd0f08c3d5650707a3f8
|
2.0 MB | Preview Download |
md5:6861aee75328084eb8f16c3be7fc14a3
|
1.0 MB | Download |
md5:92f9a168972d979438e65da74e53c6ff
|
2.4 MB | Download |
Additional details
- PMCID
- PMC5409222
- Eprint ID
- 75016
- DOI
- 10.1021/acscentsci.6b00361
- Resolver ID
- CaltechAUTHORS:20170310-084018084
- Shenzhen UV-ChemTech Inc.
- NIH Predoctoral Fellowship
- 5T32GM007616-37
- American Cancer Society
- Heritage Medical Research Institute
- NIH
- RGM097582-01
- NIH
- R35GM118191-01
- Eli Lilly
- Novartis
- Created
-
2017-03-10Created from EPrint's datestamp field
- Updated
-
2022-03-29Created from EPrint's last_modified field
- Caltech groups
- Heritage Medical Research Institute